News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Kim M. Hirshfield

Articles by Kim M. Hirshfield

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

BySara M. Tolaney, MD, MPH,Paolo D’Amico,Liyi Jia,Kim M. Hirshfield,Fatima Cardoso

April 16th 2025

Latest Updated Articles

Trending on CancerNetwork

Study Finds Increased Incidence of Cardiovascular Disease Among Patients With Cancer

Investigational NDA Submitted to FDA for CD-19+ Lymphoma/Leukemia

Developer Submits 510(k) Premarket Notification for SC Infusion System in HER2+ BC

Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer

Frontline Sorafenib Shows Promising Outcomes in Metastatic Uveal Melanoma